Communiqués Takeda Pharmaceutical Company Limited NYSE

Actions

TAK

US8740602052

Produits pharmaceutiques

Marché Fermé - NYSE Autres places de cotation 22:00:03 24/07/2026			Varia. 5j.	Varia. 1 janv.
17,24 ^USD	+2,50%		+0,52%	+10,58%

24/07	Les actions asiatiques cotées aux États-Unis sous forme d'ADR en repli lors de la séance de vendredi	MT
24/07	TAKEDA PHARMACEUTICAL COMPANY LIMITED : China Merchants Securities reste à l'achat	ZM

Communiqués

23/07	Takeda Pharmaceutical : ORZEYFUL (oveporexton) Approved in China as First Orexin Agonist and Only Medicine to Treat Narcolepsy Type 1	PU
17/07	Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies	BU
16/07	Takeda Pharmaceutical : to Hold Earnings Call for Fiscal Year 2026 1st Quarter on July 30	PU
13/07	Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products	BU
09/07	Takeda Pharmaceutical : Filing of Corporate Governance Report to the Tokyo Stock Exchange	PU
08/07	Takeda Pharmaceutical : Completed Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees	PU
24/06	Takeda Pharmaceutical : Integrated Report (AIR 2026 EN)	PU
24/06	Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO	BU
15/06	New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1	BU
11/06	Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations	BU
09/06	U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease	BU
09/06	Takeda Pharmaceutical : Notice Concerning Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan	PU
05/06	Takeda Pharmaceutical : Updates FY2025 Financial Results Based on Impact of AMITIZA® Antitrust Verdict	PU
01/06	Takeda Pharmaceutical : Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan	PU
19/05	Takeda Pharmaceutical Company Limited: Takeda Provides an Update regarding Jury Verdict in AMITIZA® (lubiprostone) Antitrust Litigation in the U.S. and Related Revision to FY2025 Financial Results	EQ
19/05	Takeda Pharmaceutical : Provides an Update regarding Jury Verdict in AMITIZA® (lubiprostone) Antitrust Litigation in the U.S. and Related Revision to FY2025 Financial Results	PU
18/05	Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda	BU
16/05	Pharmaceutical company Takeda announces sweeping cutbacks; impact on Belgian division unclear	AQ
13/05	Takeda Pharmaceutical : Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Management in Japan in 2026	PU
13/05	Takeda Pharmaceutical : Earnings Report（Kessan Tanshin）Earnings Report（Kessan Tanshin）Download Earnings Report（Kessan Tanshin） (qr2025 q4 er en)	PU
13/05	Takeda Pharmaceutical : PresentationPresentationDownload Presentation (qr2025 q4 p01 en)	PU
13/05	Takeda Pharmaceutical : Quarterly Financial ReportQuarterly Financial ReportDownload Quarterly Financial Report (qr2025 q4 qfr en)	PU
13/05	Takeda Pharmaceutical : Quarterly Highlights InfographicQuarterly Highlights InfographicDownload Quarterly Highlights Infographic (FY25Q4 EN Takeda Infographic)	PU
13/05	Takeda Pharmaceutical : Clinical Trials Summary (Clinical Trial Summary May 2026)	PU
13/05	Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results	BU